The lowering of the price target from $110 to $90 by Cantor Fitzgerald suggests a less optimistic outlook on Biomarin's stock performance, which could lead to a short-term negative impact on the stock price. However, the maintained Overweight rating indicates continued confidence in the company's long-term potential.